EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 271 (2021) E3S Web Conf., 271 (2021) 02021 References
Open Access
Issue
E3S Web Conf.
Volume 271, 2021
2021 2nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)
Article Number 02021
Number of page(s) 5
Section Environmental Protection and Green Application of Energy Saving and Emission Reduction
DOI https://doi.org/10.1051/e3sconf/202127102021
Published online 15 June 2021
  1. Podlaha, O., et al., Evolution of the cancer genome. Trends Genet, 2012. 28(4): p. 155–163. [CrossRef] [PubMed] [Google Scholar]
  2. Rius, M. and F. Lyko, Epigenetic cancer therapy: rationales, targets and drugs. Oncogene, 2012. 31(39): p. 4257–4265. [CrossRef] [PubMed] [Google Scholar]
  3. Farkona, S., E.P. Diamandis, and I.M. Blasutig, Cancer immunotherapy: the beginning of the end of cancer? BMC Med, 2016. 14: p. 73. [CrossRef] [PubMed] [Google Scholar]
  4. Das, M., C. Zhu, and V.K. Kuchroo, Tim-3 and its role in regulating anti-tumor immunity. Immunological Reviews, 2017. 276(1): p. 97–111. [CrossRef] [PubMed] [Google Scholar]
  5. Wada, J. and Y.S. Kanwar, Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem, 1997. 272(9): p. 6078–6086. [CrossRef] [PubMed] [Google Scholar]
  6. Luckheeram, R.V., et al., CD4(+)T cells: differentiation and functions. Clin Dev Immunol, 2012. 2012:p.925135. [CrossRef] [PubMed] [Google Scholar]
  7. Yasinska, I.M., et al., The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol, 2019. 10: p. 1594. [CrossRef] [PubMed] [Google Scholar]
  8. Sabatos, C.A., et al., Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol, 2003. 4(11): p. 1102–1110. [CrossRef] [PubMed] [Google Scholar]
  9. Huang, Y.H., et al., CEACAM1 regulates TIM-3-mediated tolerance and exhaustion (vol 517, pg 386, 2015). Nature, 2016. 536(7616): p. 359-359. [Google Scholar]
  10. Acharya, N., C. Sabatos-Peyton, and A.C. Anderson, Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer, 2020. 8(1). [Google Scholar]
  11. Takeuchi, O. and S. Akira, Pattern recognition receptors and inflammation. Cell, 2010. 140(6): p. 805–820. [CrossRef] [PubMed] [Google Scholar]
  12. Chiba, S., et al., Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol, 2012. 13(9): p. 832–842. [Google Scholar]
  13. Nagata, S., et al., Exposure of phosphatidylserine on the cell surface. Cell Death Differ, 2016. 23(6): p. 952–961. [CrossRef] [PubMed] [Google Scholar]
  14. Verhoven, B., R.A. Schlegel, and P. Williamson, Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med, 1995. 182(5): p. 1597–1601. [CrossRef] [PubMed] [Google Scholar]
  15. DeKruyff, R.H., et al., T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol, 2010. 184(4): p. 1918–1930. [CrossRef] [PubMed] [Google Scholar]
  16. Banerjee, H. and L.P. Kane, Immune regulation by Tim-3. F1000Res, 2018. 7 : p. 316. [Google Scholar]
  17. Monney, L., et al., Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002. 415(6871): p. 536–541. [CrossRef] [PubMed] [Google Scholar]
  18. Gorman, J.V., et al., Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J Immunol, 2014. 192(7): p. 3133–3142. [CrossRef] [PubMed] [Google Scholar]
  19. Jin, H.T., et al., Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A, 2010. 107(33): p. 14733–8. [CrossRef] [PubMed] [Google Scholar]
  20. Sakuishi, K., et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 2010. 207(10): p. 2187–2194. [CrossRef] [PubMed] [Google Scholar]
  21. Zhou, Q., et al., Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 2011. 117(17): p. 4501–4510. [CrossRef] [PubMed] [Google Scholar]
  22. Yan, J., et al., Tim-3 expression defines regulatory T cells in human tumors. PLoS One, 2013. 8(3): p. e58006. [CrossRef] [PubMed] [Google Scholar]
  23. Gao, X., et al., TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression. Plos One, 2012. 7(2). [CrossRef] [PubMed] [Google Scholar]
  24. Gleason, M.K., et al., Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood, 2012. 119(13): p. 3064–3072. [CrossRef] [PubMed] [Google Scholar]
  25. Gallois, A., et al., Reversal of NK cell exhaustion in advanced melanoma patients by Tim-3 blockade. Cancer Research, 2014. 74(19). [Google Scholar]
  26. Komohara, Y., et al., The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas. Cancer Immunol Res, 2015. 3(9): p. 999–1007. [CrossRef] [PubMed] [Google Scholar]
  27. Jiang, X., et al., Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. Oncoimmunology, 2016. 5(9): p. e1211219. [CrossRef] [PubMed] [Google Scholar]
  28. Chiba, S., et al., Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature Immunology, 2012. 13(9): p. 832–842. [CrossRef] [PubMed] [Google Scholar]
  29. He, X. and C. Xu, Immune checkpoint signaling and cancer immunotherapy. Cell Res, 2020. 30(8): p. 660–669. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.